Stocks and Investing
by (remove) : Chris Shibutani
RSSJSONXMLCSV
Stocks and Investing
by (remove) : Chris Shibutani
RSSJSONXMLCSV
Fri, July 12, 2024
Fri, May 3, 2024
Mon, March 11, 2024
Wed, February 28, 2024
Mon, February 12, 2024
Mon, December 11, 2023
Fri, November 10, 2023
Mon, October 30, 2023
Wed, October 11, 2023
Mon, July 24, 2023
Tue, March 28, 2023
Tue, March 14, 2023
Tue, January 31, 2023
Mon, December 19, 2022
Mon, December 5, 2022
Tue, November 8, 2022
Fri, September 9, 2022
Tue, August 16, 2022
Tue, May 24, 2022
Wed, April 20, 2022
Tue, April 12, 2022
Fri, April 1, 2022
Thu, February 3, 2022
Tue, February 1, 2022
Fri, December 17, 2021
Tue, November 23, 2021
Tue, September 7, 2021

Chris Shibutani Maintained (AMLX) at Hold with Increased Target to $4 on, Jul 12th, 2024


Published on 2024-10-28 12:24:56 - WOPRAI, Chris Shibutani
  Print publication without navigation


Chris Shibutani of Goldman Sachs, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Hold with Increased Target from $3 to $4 on, Jul 12th, 2024.

Chris has made no other calls on AMLX in the last 4 months.



There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 2 agree with Chris's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Graig Suvannavejh of "Mizuho" Maintained at Hold with Decreased Target to $3 on, Tuesday, May 14th, 2024
  • Joel Beatty of "Baird" Maintained at Hold with Decreased Target to $3 on, Thursday, April 11th, 2024


This is the rating of the analyst that currently disagrees with Chris


  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $8 on, Wednesday, July 10th, 2024
Contributing Sources